Eribulin in liposarcoma: Added benefit not proven

(Institute for Quality and Efficiency in Health Care) Neither the results from a study of direct comparison nor from an indirect comparison were suitable for the assessment.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news